Published in Infect Immun on May 31, 2011
Synthetically defined glycoprotein vaccines: current status and future directions. Chem Sci (2013) 0.97
Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines (2014) 0.89
A scalable method for biochemical purification of Salmonella flagellin. Protein Expr Purif (2014) 0.83
Vaccine strategies against cystic fibrosis pathogens. Hum Vaccin Immunother (2016) 0.77
Pangenome-wide and molecular evolution analyses of the Pseudomonas aeruginosa species. BMC Genomics (2016) 0.77
Porcine Dendritic Cells as an In Vitro Model to Assess the Immunological Behaviour of Streptococcus suis Subunit Vaccine Formulations and the Polarizing Effect of Adjuvants. Pathogens (2017) 0.75
Flagellin as carrier and adjuvant in cocaine vaccine development. Mol Pharm (2015) 0.75
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev (1996) 13.91
Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med (2003) 9.78
Lung infections associated with cystic fibrosis. Clin Microbiol Rev (2002) 9.20
Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA (2005) 3.49
A new polysaccharide resembling alginic acid isolated from pseudomonads. J Biol Chem (1966) 3.43
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol (1997) 3.23
Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology (1999) 3.03
Role of alginate and its O acetylation in formation of Pseudomonas aeruginosa microcolonies and biofilms. J Bacteriol (2001) 2.87
Genetic analysis of the alginate biosynthetic gene cluster of Pseudomonas aeruginosa shows evidence of an operonic structure. Mol Microbiol (1993) 2.59
Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Mol Microbiol (2005) 2.49
TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system. Semin Immunopathol (2007) 2.42
Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun (2000) 2.41
Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol (2002) 2.22
Pseudomonas aeruginosa flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5. Am J Respir Cell Mol Biol (2003) 2.09
Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun (2006) 1.92
Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis. Infect Immun (2001) 1.79
A genomic island in Pseudomonas aeruginosa carries the determinants of flagellin glycosylation. Proc Natl Acad Sci U S A (2001) 1.77
Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients. J Clin Microbiol (1986) 1.76
Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. N Engl J Med (1987) 1.59
Mucosal administration of flagellin induces innate immunity in the mouse lung. Infect Immun (2004) 1.56
Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun (1999) 1.54
Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun (2004) 1.49
Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol (2004) 1.45
Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J Immunol (2008) 1.45
Chemistry and biology of the alginate of mucoid strains of Pseudomonas aeruginosa in cystic fibrosis. Mol Aspects Med (1988) 1.41
Roles of specific amino acids in the N terminus of Pseudomonas aeruginosa flagellin and of flagellin glycosylation in the innate immune response. Infect Immun (2005) 1.38
Pseudomonas aeruginosa LPS or flagellin are sufficient to activate TLR-dependent signaling in murine alveolar macrophages and airway epithelial cells. PLoS One (2009) 1.35
Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol (2008) 1.33
Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine (2007) 1.31
Alginate production by clinical nonmucoid Pseudomonas aeruginosa strains. J Clin Microbiol (1987) 1.28
A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A (2007) 1.27
Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J Immunol (2009) 1.20
Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J Immunol (2010) 1.15
Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect Immun (2003) 1.15
Flagellar activation of epithelial signaling. Am J Respir Cell Mol Biol (2006) 1.15
Mucosal adjuvant activity of flagellin in aged mice. Mech Ageing Dev (2008) 1.12
Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. J Immunol (2008) 1.11
Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses. Infect Immun (2005) 1.07
Role of Toll-like receptor 5 in the innate immune response to acute P. aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol (2009) 1.07
Monomer composition and sequence of alginates from Pseudomonas aeruginosa. Int J Biol Macromol (2002) 1.06
Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines. Infect Immun (2009) 1.04
Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide. Infect Immun (1990) 1.03
Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect Immun (1994) 1.01
Genotypic and phenotypic characteristics of Pseudomonas aeruginosa isolates associated with ulcerative keratitis. J Med Microbiol (2005) 1.01
Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine. J Immunol (2007) 0.96
Recognition of mucin components by Pseudomonas aeruginosa. Glycoconj J (2001) 0.94
Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate. J Med Microbiol (2006) 0.93
Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine. Infect Immun (1991) 0.89
Antibodies raised against N'-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection. Int J Mol Med (2005) 0.89
Electron beam fragmentation of bacterial polysaccharides as a method of producing oligosaccharides for the preparation of conjugate vaccines. FEMS Microbiol Lett (1999) 0.78
Lung infections associated with cystic fibrosis. Clin Microbiol Rev (2002) 9.20
Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide. Infect Immun (2002) 3.14
Intraspecific diversity of Yersinia pestis. Clin Microbiol Rev (2004) 3.03
Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog (2008) 2.80
Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun (2005) 2.37
The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-beta-1-6-N-acetylglucosamine, which is critical for biofilm formation. J Bacteriol (2009) 2.06
Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms. Antimicrob Agents Chemother (2005) 1.91
High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection. Clin Infect Dis (2010) 1.84
The teicoplanin-associated locus regulator (TcaR) and the intercellular adhesin locus regulator (IcaR) are transcriptional inhibitors of the ica locus in Staphylococcus aureus. J Bacteriol (2004) 1.81
Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection. Infect Immun (2005) 1.80
The physiology and collective recalcitrance of microbial biofilm communities. Adv Microb Physiol (2002) 1.76
Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa. Am J Physiol Cell Physiol (2009) 1.72
Methicillin resistance alters the biofilm phenotype and attenuates virulence in Staphylococcus aureus device-associated infections. PLoS Pathog (2012) 1.72
Immune-activating properties of Panton-Valentine leukocidin improve the outcome in a model of methicillin-resistant Staphylococcus aureus pneumonia. Infect Immun (2012) 1.70
Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. J Infect Dis (2005) 1.62
Identification of a 5-nucleotide sequence that controls expression of the ica locus in Staphylococcus aureus and characterization of the DNA-binding properties of IcaR. Mol Microbiol (2003) 1.61
Localization of cystic fibrosis transmembrane conductance regulator to lipid rafts of epithelial cells is required for Pseudomonas aeruginosa-induced cellular activation. J Immunol (2004) 1.56
Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect Immun (2006) 1.52
Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia. Infect Immun (2009) 1.52
ClpXP proteases positively regulate alginate overexpression and mucoid conversion in Pseudomonas aeruginosa. Microbiology (2008) 1.52
Cochlin produced by follicular dendritic cells promotes antibacterial innate immunity. Immunity (2013) 1.50
Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci U S A (2010) 1.49
Isolation, structural characterization, and immunological evaluation of a high-molecular-weight exopolysaccharide from Staphylococcus aureus. Carbohydr Res (2003) 1.44
CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci U S A (2002) 1.44
IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol (2008) 1.42
Transcription of quorum-sensing system genes in clinical and environmental isolates of Pseudomonas aeruginosa. J Bacteriol (2003) 1.40
Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc Natl Acad Sci U S A (2003) 1.40
Quantitative analysis of adhesion and biofilm formation on hydrophilic and hydrophobic surfaces of clinical isolates of Staphylococcus epidermidis. Res Microbiol (2005) 1.38
Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun (2007) 1.35
Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia. Infect Immun (2005) 1.34
A comprehensive analysis of in vitro and in vivo genetic fitness of Pseudomonas aeruginosa using high-throughput sequencing of transposon libraries. PLoS Pathog (2013) 1.34
Protection against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide. Proc Natl Acad Sci U S A (2007) 1.34
Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry. J Antimicrob Chemother (2005) 1.33
Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine (2007) 1.31
Host resistance to lung infection mediated by major vault protein in epithelial cells. Science (2007) 1.30
Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor. Infect Immun (2007) 1.30
Pseudomonas aeruginosa-induced apoptosis is defective in respiratory epithelial cells expressing mutant cystic fibrosis transmembrane conductance regulator. Am J Respir Cell Mol Biol (2003) 1.30
Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide. Vaccine (2004) 1.29
Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens. Infect Immun (2009) 1.29
Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens. Proc Natl Acad Sci U S A (2013) 1.23
Temperature-dependent variations and intraspecies diversity of the structure of the lipopolysaccharide of Yersinia pestis. Biochemistry (2005) 1.21
Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Trends Mol Med (2008) 1.21
The galU Gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung. Infect Immun (2004) 1.18
Conserved and variable structural features in the lipopolysaccharide of Pseudomonas aeruginosa. J Endotoxin Res (2006) 1.17
Poly-N-acetyl-β-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections. Infect Immun (2011) 1.17
Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc Natl Acad Sci U S A (2007) 1.17
Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect Immun (2003) 1.15
Salmonella enterica serovar typhi modulates cell surface expression of its receptor, the cystic fibrosis transmembrane conductance regulator, on the intestinal epithelium. Infect Immun (2002) 1.14
Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect Immun (2003) 1.13
Inactivation of the rhlA gene in Pseudomonas aeruginosa prevents rhamnolipid production, disabling the protection against polymorphonuclear leukocytes. APMIS (2009) 1.12
Alveolar inflammation in cystic fibrosis. J Cyst Fibros (2010) 1.11
The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. J Infect Dis (2005) 1.11
Comparative antibody-mediated phagocytosis of Staphylococcus epidermidis cells grown in a biofilm or in the planktonic state. Infect Immun (2006) 1.10
Inhibition of macrophage migration inhibitory factor ameliorates ocular Pseudomonas aeruginosa-induced keratitis. PLoS Pathog (2010) 1.10
Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. Infect Immun (2002) 1.08
Intraspecies and temperature-dependent variations in susceptibility of Yersinia pestis to the bactericidal action of serum and to polymyxin B. Infect Immun (2005) 1.07
Wall teichoic acids are dispensable for anchoring the PNAG exopolysaccharide to the Staphylococcus aureus cell surface. Microbiology (2008) 1.06
Effects of growth in the presence of subinhibitory concentrations of dicloxacillin on Staphylococcus epidermidis and Staphylococcus haemolyticus biofilms. Appl Environ Microbiol (2005) 1.05
Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing. Proc Natl Acad Sci U S A (2013) 1.05
Impact of Drug Resistance on Virulence and Fitness of Bacterial Pathogens. Crit Care Med (2016) 1.05
Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines. Infect Immun (2009) 1.04
Influence of cystic fibrosis transmembrane conductance regulator on gene expression in response to Pseudomonas aeruginosa infection of human bronchial epithelial cells. Infect Immun (2005) 1.03
Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatr Pulmonol (2007) 1.02
Synthesis of beta-(1-->6)-linked glucosamine oligosaccharides corresponding to fragments of the bacterial surface polysaccharide poly-N-acetylglucosamine. Carbohydr Res (2006) 1.00
Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii. J Bacteriol (2012) 1.00
Comparative evaluation of coagulase-negative staphylococci (CoNS) adherence to acrylic by a static method and a parallel-plate flow dynamic method. Res Microbiol (2004) 0.99
Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients. Pediatr Pulmonol (2008) 0.98
Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy. Clin Infect Dis (2012) 0.98
IL1B polymorphisms modulate cystic fibrosis lung disease. Pediatr Pulmonol (2009) 0.98
Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. J Clin Invest (2010) 0.98
Role of neutrophils, MyD88-mediated neutrophil recruitment, and complement in antibody-mediated defense against Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci (2009) 0.98
Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection. Infect Immun (2010) 0.97
Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis (2012) 0.96
On the greatly exaggerated reports of the death of infectious diseases. Clin Infect Dis (2008) 0.96
Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections. Infect Immun (2012) 0.96
A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infect Immun (2006) 0.96
Caveolin-1 modifies the immunity to Pseudomonas aeruginosa. J Immunol (2009) 0.95
Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens. PLoS One (2012) 0.95
The relationship between inhibition of bacterial adhesion to a solid surface by sub-MICs of antibiotics and subsequent development of a biofilm. Res Microbiol (2005) 0.95
Structures of the core oligosaccharide and O-units in the R- and SR-type lipopolysaccharides of reference strains of Pseudomonas aeruginosa O-serogroups. FEMS Immunol Med Microbiol (2006) 0.95
Hepoxilin A(3) facilitates neutrophilic breach of lipoxygenase-expressing airway epithelial barriers. J Immunol (2012) 0.94
Hypoxia increases corneal cell expression of CFTR leading to increased Pseudomonas aeruginosa binding, internalization, and initiation of inflammation. Invest Ophthalmol Vis Sci (2004) 0.94
Utility of in vivo transcription profiling for identifying Pseudomonas aeruginosa genes needed for gastrointestinal colonization and dissemination. PLoS One (2010) 0.94
Structural studies on the core and the O-polysaccharide repeating unit of Pseudomonas aeruginosa immunotype 1 lipopolysaccharide. Eur J Biochem (2002) 0.93
Cold temperature-induced modifications to the composition and structure of the lipopolysaccharide of Yersinia pestis. Carbohydr Res (2005) 0.91
Disruption of CFTR-dependent lipid rafts reduces bacterial levels and corneal disease in a murine model of Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci (2008) 0.91
Relationship of the lipopolysaccharide structure of Yersinia pestis to resistance to antimicrobial factors. Adv Exp Med Biol (2007) 0.90
Development of DNA vaccines against hemolytic-uremic syndrome in a murine model. Infect Immun (2003) 0.90
Is exposure to mercury a driving force for the carriage of antibiotic resistance genes? J Med Microbiol (2010) 0.88
Structure of the lipopolysaccharide of Pseudomonas aeruginosa O-12 with a randomly O-acetylated core region. Carbohydr Res (2003) 0.88
Topical neutralization of interleukin-17 during experimental Pseudomonas aeruginosa corneal infection promotes bacterial clearance and reduces pathology. Infect Immun (2012) 0.87
Staphylococcus aureus corneal infections: effect of the Panton-Valentine leukocidin (PVL) and antibody to PVL on virulence and pathology. Invest Ophthalmol Vis Sci (2013) 0.87
Effect of deletion of the lpxM gene on virulence and vaccine potential of Yersinia pestis in mice. J Med Microbiol (2007) 0.87
Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods. PLoS One (2011) 0.86
Immunization with a chimera consisting of the B subunit of Shiga toxin type 2 and brucella lumazine synthase confers total protection against Shiga toxins in mice. J Immunol (2013) 0.86
Interleukin-10 and interferon-gamma modulate surface expression of fractalkine-receptor (CX(3)CR1) via PI3K in monocytes. Immunology (2009) 0.85
Collaboration between macrophages and vaccine-induced CD4+ T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia. J Infect Dis (2012) 0.85